Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction.

Wynn SS, Nagabundi S, Koo J, Chin NW.

Arch Pathol Lab Med. 2000 Jul;124(7):1074-6.

PMID:
10888786
[PubMed - indexed for MEDLINE]
2.

Prostatic marker-negative amphicrine carcinoma of the prostate.

Papadimitriou JC, Weihing RR, Choi C, Drachenberg CB.

Ultrastruct Pathol. 1994 May-Jun;18(3):357-63.

PMID:
7520642
[PubMed - indexed for MEDLINE]
3.

Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.

Turbat-Herrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE, Bonnin JM.

Arch Pathol Lab Med. 1988 Nov;112(11):1100-5.

PMID:
2460064
[PubMed - indexed for MEDLINE]
4.

Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.

Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, Meria P, Teillac P, Fiet J, Le Duc A.

J Urol. 1996 Apr;155(4):1340-3.

PMID:
8632569
[PubMed - indexed for MEDLINE]
5.

Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.

Yashi M, Terauchi F, Nukui A, Ochi M, Yuzawa M, Hara Y, Morita T.

Urol Oncol. 2006 Jul-Aug;24(4):313-7.

PMID:
16818183
[PubMed - indexed for MEDLINE]
6.

Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.

Cussenot O, Villette JM, Cochand-Priollet B, Berthon P.

Prostate Suppl. 1998;8:43-51. Review.

PMID:
9690663
[PubMed - indexed for MEDLINE]
7.

Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.

Jiborn T, Abrahamson M, Gadaleanu V, Lundwall A, Bjartell A.

BJU Int. 2006 Jul;98(1):189-96.

PMID:
16831167
[PubMed - indexed for MEDLINE]
8.

Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.

Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE.

Cancer. 1993 Jun 15;71(12):3952-65.

PMID:
7685237
[PubMed - indexed for MEDLINE]
9.

Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.

Wang W, Epstein JI.

Am J Surg Pathol. 2008 Jan;32(1):65-71.

PMID:
18162772
[PubMed - indexed for MEDLINE]
10.

A case of synchronous double primary lung cancer with neuroendocrine features.

Niho S, Yokose T, Nagai K, Nishiwaki Y, Kodama T, Mukai K.

Jpn J Clin Oncol. 1999 Apr;29(4):219-25.

PMID:
10340047
[PubMed - indexed for MEDLINE]
Free Article
11.

Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.

Cox ME, Deeble PD, Lakhani S, Parsons SJ.

Cancer Res. 1999 Aug 1;59(15):3821-30.

PMID:
10447001
[PubMed - indexed for MEDLINE]
Free Article
12.

Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.

Kimura N, Hoshi S, Takahashi M, Takeha S, Shizawa S, Nagura H.

J Urol. 1997 Feb;157(2):565-8.

PMID:
8996358
[PubMed - indexed for MEDLINE]
13.

Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?

Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL.

Prostate. 1997 Jan 1;30(1):1-6.

PMID:
9018329
[PubMed - indexed for MEDLINE]
14.

Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.

Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L.

J Urol. 2002 Sep;168(3):1204-11.

PMID:
12187268
[PubMed - indexed for MEDLINE]
15.

Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: a report of two cases.

Mai KT, Commons AS, Perkins DG, Yazdi HM, Collins JP.

Hum Pathol. 1996 Dec;27(12):1377-81.

PMID:
8958315
[PubMed - indexed for MEDLINE]
16.

A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ.

Cancer Res. 2001 Mar 1;61(5):2239-49.

PMID:
11280793
[PubMed - indexed for MEDLINE]
Free Article
17.

Divergent neuroendocrine differentiation in prostatic carcinoma.

di Sant' Agnese PA.

Semin Diagn Pathol. 2000 May;17(2):149-61. Review.

PMID:
10839615
[PubMed - indexed for MEDLINE]
18.

Neuroendocrine differentiation in prostatic carcinoma.

Abrahamsson PA.

Prostate. 1999 May;39(2):135-48. Review.

PMID:
10221570
[PubMed - indexed for MEDLINE]
19.

Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.

Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H.

J Urol. 2002 Feb;167(2 Pt 1):512-5.

PMID:
11792908
[PubMed - indexed for MEDLINE]
20.

Prostatic ductal adenocarcinoma showing Bcl-2 expression.

Tulunay O, Orhan D, Baltaci S, Gögüş C, Müftüoglu YZ.

Int J Urol. 2004 Sep;11(9):805-8.

PMID:
15379952
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk